Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Healthy Adult Immune Response Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Gamma Tocopherol-enriched Supplement on Lower Airway Responses to Inhaled Wood Smoke in Healthy Adults

NCT03444298
View directory record Official record
Conditions
Airway Inflammation, Asthma
Interventions
Gamma Tocopherol, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2024 · Synced Jul 23, 2026, 2:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study of West Nile Virus Vaccine

NCT00300417
View directory record Official record
Conditions
West Nile Fever
Interventions
VRC-WNVDNA020-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 2:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Immune Response to Heplisav in Healthy Older Adults

NCT01999699
View directory record Official record
Conditions
Hepatitis B
Interventions
HEPLISAV
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
50 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Jul 23, 2026, 2:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults

NCT00089908
View directory record Official record
Conditions
Dengue Fever
Interventions
rDEN1delta30, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2008 · Synced Jul 23, 2026, 2:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults

NCT04723602
View directory record Official record
Conditions
Ebola Virus Disease, Marburg Virus Disease
Interventions
cAd3-Marburg, cAd3-EBO-S
Biological
Lead sponsor
Albert B. Sabin Vaccine Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Jul 23, 2026, 2:57 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine

NCT05047770
View directory record Official record
Conditions
Herpes Zoster
Interventions
HZ/su, Flu D-QIV, mRNA-1273
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
2,013 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
46
States / cities
Tempe, Arizona • Oxnard, California • San Diego, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Jul 23, 2026, 2:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy Adults

NCT00094705
View directory record Official record
Conditions
Dengue Fever
Interventions
rDEN2/4delta30(ME) Vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 20, 2008 · Synced Jul 23, 2026, 2:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector

NCT00801697
View directory record Official record
Conditions
HIV Infections
Interventions
DNA Vaccine, DNA Vaccine placebo, rAd35, rAd35 placebo, rAd5, rAd5 placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Jul 23, 2026, 2:57 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults

NCT05108818
View directory record Official record
Conditions
Influenza, Human
Interventions
Seasonal influenza vaccine
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jul 23, 2026, 2:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults

NCT01260727
View directory record Official record
Conditions
HIV Infections
Interventions
PENNVAX-G DNA Vaccine, MVA-CMDR Vaccine, Placebo PENNVAX-G Vaccine, Placebo MVA-CMDR Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 23, 2026, 2:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to an Adenoviral HIV-1 Vaccine in Healthy Adults

NCT00618605
View directory record Official record
Conditions
HIV Infections
Interventions
Ad26.ENVA.01 HIV-1 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 23, 2026, 2:57 AM EDT
Completed Phase 1 Interventional

Experimental PfSPZ Vaccine in Adults Without Malaria

NCT01441167
View directory record Official record
Conditions
Malaria, Prevention and Control, Acquired Immunity
Interventions
PfSPZ
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Jul 23, 2026, 2:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Group Study of the Safety of and Immune Response to a Single Dose of Bird Flu Vaccine (H7N3) in Healthy Adults

NCT00853255
View directory record Official record
Conditions
Influenza, Virus Diseases
Interventions
Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced Jul 23, 2026, 2:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults Who Have Participated in Previous HIV Vaccine Clinical Trials and in Adults Who Have Not Participated in Previous HIV Vaccine Clinical Trials

NCT01376726
View directory record Official record
Conditions
HIV Infections
Interventions
Sub C gp140 Vaccine, MF59C.1 Adjuvant
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
3
States / cities
Birmingham, Alabama • Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Jul 23, 2026, 2:57 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults

NCT06803342
View directory record Official record
Conditions
Ebola Sudan Virus Disease
Interventions
cAd3-Sudan Vaccine, Placebo
Biological
Lead sponsor
Albert B. Sabin Vaccine Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
4
States / cities
Phoenix, Arizona • Melbourne, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jul 23, 2026, 2:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Vaccine to Prevent West Nile Virus Disease

NCT00106769
View directory record Official record
Conditions
Healthy, West Nile Fever, Healthy Volunteer, HV
Interventions
VRC-WNVDNA017-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 2:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Four Chimera Cytomegalovirus (CMV) Vaccines in Healthy Adult Males 30-50 Years of Age

NCT01195571
View directory record Official record
Conditions
Cytomegalovirus
Interventions
cmv vaccine
Biological
Lead sponsor
CMV Research Foundation
Other
Eligibility
30 Years to 50 Years · Male only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 18, 2015 · Synced Jul 23, 2026, 2:57 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

NCT06069544
View directory record Official record
Conditions
Malaria
Interventions
BNT165e, Placebo
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 55 Years
Enrollment
163 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
5
States / cities
Tempe, Arizona • Baltimore, Maryland • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 23, 2026, 2:57 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years

NCT06573281
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Investigational RSV vaccine 1, Investigational RSV vaccine 2, Investigational RSV vaccine 3, Investigational RSV vaccine 4, Investigational RSV vaccine 5, Investigational RSV vaccine 6, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
5
States / cities
Rolling Hills Estates, California • Atlanta, Georgia • Lenexa, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Jul 23, 2026, 2:57 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults

NCT05089630
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
Pentamer (low)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(med)/Adjuvant vaccine, Pentamer (high)/gB(med)/Adjuvant vaccine, Placebo (saline solution)
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
18
States / cities
Anaheim, California • Long Beach, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 23, 2026, 2:57 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Vaccination Responses in Young and Older Adults

NCT02654704
View directory record Official record
Conditions
Individuality, Healthy, Asthma, Immune System and Related Disorders
Interventions
Pneumococcal Vaccination
Biological
Lead sponsor
Michigan State University
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Jul 23, 2026, 2:57 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Influenza-Specific Immune Responses in Children and Adults During the 2010-2011 Influenza Season in the U.S.

NCT01262079
View directory record Official record
Conditions
Influenza
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
4
States / cities
Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2011 · Synced Jul 23, 2026, 2:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza

NCT06179446
View directory record Official record
Conditions
Grippe, Influenza, Vaccines
Interventions
pdmFlu vaccine, Placebo, Licensed influenza vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 84 Years
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
3
States / cities
New Haven, Connecticut • Hollywood, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jul 23, 2026, 2:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults

NCT00118924
View directory record Official record
Conditions
Tick-Borne Encephalitis
Interventions
LGT(TP21)/DEN4, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 20, 2008 · Synced Jul 23, 2026, 2:57 AM EDT